Research
Immunotargeting and Radiobiology in Oncology : A. Pèlegrin

RESEARCH TOPICS

Our research is organized around 3 closely related research themes

  • Human Epidermal Receptor (HER) family: from combinations of approved monoclonal antibodies (mAbs) to original mAbs against receptors and ligands, and back
  • MISR-II: the original ovarian carcinoma target
  • Severe late adverse effects after radiotherapy: analysis of the causes and design of a predictive assay

 

Research Summary

Our research focuses on the treatment of solid tumors by using antibodies and radiotherapy with a special attention to drug-induced resistance. To this aim, we design, develop and evaluate monoclonal antibodies (mAbs) to target antigens the expression of which is enhanced when tumors become resistant to a treatment and we combine them to identify synthetic lethal interactions for anti-cancer drug discovery/improvement.

 

Our main objectives are: (i) to design and develop new antibodies and derived molecules; (ii) to improve the efficacy of these targeted therapeutic approaches; and (iii) to understand the underlying mechanisms of action.

Lire la suite

MAIN PUBLICATIONS

Ogier C, Colombo P-E, Bousquet C, Canterel-Thouennon L, Sicard P, Garambois V, Thomas G, Gaborit N, Jarlier M, Pirot N, Pugnière M, Vie N, Gongora C, Martineau P, Robert B, Pèlegrin A, Chardès T, Larbouret C Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett.. 2018;432. doi:10.1016/j.canlet.2018.06.023

Boogerd L, Hoogstins C, Schaap D, Kusters M, Handgraaf H, van der Valk M, Hilling D, Holman F, Peeters K, Mieog J, van de Velde C, Farina-Sarasqueta A, van Lijnschoten I, Framery B, Pèlegrin A, Gutowski M, Nienhuijs S, de Hingh I, Nieuwenhuijzen G, Rutten H, Burggraaf J, Vahrmeijer A Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181-191. doi:10.1016/S2468-1253(17)30395-3

Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul M, Mondon P, Barret J, Mathis G, Prost J, Pelegrin A, Chardes T Neuregulin 1 allosterically enhances the anti-tumor effects of the non-competing anti-HER3 antibody 9F7-F11 by increasing its binding to HER3. Mol Cancer Ther. 2017;6. doi:10.1158/1535-7163.MCT-16-0886

Azria D, Riou O, Castan F, Nguyen T, Peignaux K, Lemanski C, Lagrange J, Kirova Y, Lartigau E, Belkacemi Y, Bourgier C, Rivera S, Noel G, Clippe S, Mornex F, Hennequin C, Kramar A, Gourgou S, Pelegrin A, Fenoglietto P, Ozsahin E Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. EBioMedicine. 2015;2. doi:10.1016/j.ebiom.2015.10.024


Team

Responsable : André Pèlegrin

Institut de Recherche en
Cancérologie de Montpellier
CRLC Val d’Aurelle-Paul Lamarque
34298 Montpellier cedex 5

Tél. : 33 (0)4 67 61 30 32
Fax : 33 (0)4 67 61 37 87
andre.pelegrin@inserm.fr

 

 

Partners and Funding

  

     

 


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés